Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 68% of resolved cases
Nelson B Moseley II is an examiner in Tech Center 1600 and Art Unit 1642. He has 628 resolved cases, with an allowance rate of 68.0 percent. The median days to allowance is 1140. These figures suggest a moderate probability of success and a relatively long period for prosecution in this unit.
The interview lift is 41.5 percent, which is a significant metric. This figure indicates that interviews are a powerful tool for obtaining an allowance with this examiner. A 41.5 percent lift suggests that many cases are successfully resolved through direct communication compared to the 68.0 percent baseline. Practitioners should prioritize interviews given this data.
The 628 resolved cases provide a reliable dataset for Art Unit 1642. The allowance rate and 1140 day median are important for managing client expectations. The interview lift is the most significant metric for practitioners to consider when developing their prosecution strategy for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 17759382 | SELF-ASSEMBLING PRODRUGS AS IMMUNE BOOSTERS FOR CANCER IMMUNOTHERAPY | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17813100 | COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18324773 | Zwitterion Polymer-Drug Conjugates | Non-Final OA | University of Utah Research Foundation |
| 18048747 | DUAL TARGETED IMMUNE REGULATING COMPOSITIONS | Non-Final OA | Seismic Therapeutic, Inc. |
| 18316739 | Antibody Constructs for CLDN18.2 and CD3 | Final Rejection | AMGEN INC. |
| 17480504 | Means and Methods for Treating Tumorous Diseases | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
| 19011427 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18392127 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | Final Rejection | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy